Delhi HC: Education Department Cannot Restrict Recruitment in Aided Minority Schools  ||  Allahabad HC: Senior Citizens Act Cannot Decide Title Disputes Unless Transfer Challengeable  ||  Bombay HC: Family Arrangement Execution Alone Not Proof of HUF Property Admission  ||  Patna HC: BAU Statutes Cannot Convert 2011 Direct Recruitment into Tenure Appointment  ||  P&H HC: Dressing Pet Dog as Lord Krishna Out of Devotion is Not Offence and Does Not Hurt Sentiments  ||  J&K HC Quashes 2016 Case Against Coca-Cola Over in Dual Pricing MRPs Allegations  ||  Supreme Court Explains the Grounds for Declaring a Judgment Per Incuriam  ||  SC: Summoning Hotel Records, Phone Data to Prove Adultery Does Not Breach Privacy Rights  ||  SC: Magistrates Should Not Record Prosecution Evidence in Sessions-Triable Cases  ||  Supreme Court Lays Down Guidelines on Using ITRs to Assess Motor Accident Victims' Income    

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK   MERCK   PATENT   DIABETES  

Share :        

Disclaimer | Copyright 2026 - All Rights Reserved